Should You Continue to Hold STERIS Stock in Your Portfolio Now?

STERIS plc (STE), a Zacks Rank #3 (Hold), demonstrated robust operational performance in fiscal Q4 2025, with its Healthcare segment achieving 6% organic growth and the Applied Sterilization Technologies (AST) division growing 9%, driven by U.S. procedure volumes, pricing gains, and increased biopharma demand. The company also notably strengthened its financial position, reducing long-term debt by 38.5% to $1.92 billion and ending the period with more cash than short-term debt. However, the outlook is tempered by ongoing macroeconomic pressures, including rising healthcare costs and input prices, alongside increasing customer consolidation within the healthcare industry, which pose potential headwinds to future growth.

Analysis

STERIS plc (STE) demonstrates a solid operational footing contrasted by significant external headwinds, supporting its 'Hold' rating. The company's fiscal fourth-quarter results were robust, with the Healthcare segment delivering 6% constant currency organic revenue growth, driven by a 13% increase in service revenues and strong order growth of over 12%. Similarly, the Applied Sterilization Technologies (AST) segment grew 9% year-over-year, benefiting from stable MedTech demand and initial signs of a recovery in bioprocessing. A key highlight is the substantial improvement in the company's financial position; long-term debt was reduced by 38.5% year-over-year to $1.92 billion, and the total debt-to-capital ratio fell to 22.5%. This deleveraging, combined with a cash position exceeding short-term debt, signals disciplined capital management. However, these strengths are tempered by persistent macroeconomic challenges, including healthcare cost containment pressures and potential raw material price volatility. Furthermore, the ongoing trend of customer consolidation poses a direct threat to pricing power and market share. While the stock has outperformed its industry by a wide margin over the past year (a 6.2% gain versus a 12.2% industry decline), it has lagged the S&P 500, and fiscal 2026 consensus earnings estimates have seen only a modest 0.9% upward revision.

Key Decisions for Investors

• Given the balance between strong execution and significant external risks, maintaining a neutral or 'Hold' position appears justified while monitoring for changes in the operating environment.
• Investors should closely track company margins in subsequent quarters for any signs of erosion from the dual pressures of customer consolidation and input cost inflation.
• The nascent recovery in bioprocessing demand for the AST segment is a key potential catalyst; confirmation of this trend's acceleration could provide a positive inflection point for the stock.
• Considering the stock's performance lag against the S&P 500 and the mention of better-ranked peers, it would be prudent to conduct a relative value analysis against names like CAH and COR to assess sector allocation.